Kymera Therapeutics(US:KYMR)2025-02-27 14:47Business Highlights - Kymera Therapeutics introduced its immunology development strategy and unveiled two new programs: STAT6 and TYK2[7] - The company filed and cleared KT-621 (STAT6) IND and initiated a Phase 1 healthy volunteer trial[7] - KT-295 (TYK2) was declared as the lead development candidate[7] - Kymera Therapeutics raised approximately $600 million, extending the cash runway into mid-2027[7] Clinical Development - KT-621 (STAT6): Phase 1b study in atopic dermatitis patients is expected to start in 2Q25, with results reported in 4Q25; Phase 2b study in atopic dermatitis patients is planned for 4Q25, followed by a Phase 2b study in asthma patients in 1Q26[9] - KT-295 (TYK2): Phase 1 trial in healthy volunteers is expected to begin in 2Q25, with results reported in 4Q25[9] - KT-474 (IRAK4): Phase 2b trials in hidradenitis suppurativa (HS) and atopic dermatitis (AD) are ongoing, with primary completion expected in 1H 2026 (HS) and mid-2026 (AD)[23] Financial Results - Collaboration revenue for the three months ended December 31, 2024, was $7394 thousand, compared to $47884 thousand for the same period in 2023[25] - Research and development expenses for the three months ended December 31, 2024, were $71818 thousand, compared to $52970 thousand for the same period in 2023[25] - Net loss for the three months ended December 31, 2024, was $70753 thousand, compared to $14369 thousand for the same period in 2023[25] - Cash, cash equivalents, and marketable securities totaled $850903 thousand as of December 31, 2024, compared to $436315 thousand as of December 31, 2023[25]